CCMEP™ is the only credential that designates qualified individuals as Certified CME Professionals.

Test Development in
collaboration with:

Buy Erlotinib (Tarceva) online on NC-CME
Erlotinib (trade names include Tarceva, Erlocip, Erlonat, Zyceva) is an anti-cancer medication from protein kinase inhibitors pharmacological group. This medicine is used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works as an epidermal growth factor receptor inhibitor (EGFR inhibitor).

How and where to order Erlotinib (Tarceva) 150 mg tablets online:



Prices: from $34.30 per bottle
Discount: 5% coupon: 5OFF
Forms: Tarceva (Erlotinib) 150 mg tablets
Quantity: 30 bottles
Type: Tarceva generic, Erlonat brand
Payment: Visa, MasterCard, AmEx, JCB, Bitcoin
Delivery: Unregistered Mail or Trackable Courier
Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Related medications:

  • Afatinib (Gilotrif )
  • Alectinib (Alecensa)
  • Cabozantinib (Cabometyx, Cometriq)
  • Crizotinib (Xalkori)
  • Dabrafenib (Tafinlar)
  • Entrectinib (Rozlytrek)
  • Everolimus (Zortress, Certican)
  • Icotinib (Conmana)
  • Imatinib (Gleevec)
  • Lapatinib (Tykerb, Tyverb)
  • Lenvatinib (Lenvima, Lenvanix)
  • Midostaurin (Rydapt)
  • Neratinib (Nerlynx)
  • Nilotinib (Tasigna)
  • Palbociclib (Ibrance)
  • Quizartinib (Vanflyta)
  • Ribociclib (Kisqali)
  • Ridaforolimus (Deforolimus)
  • Sorafenib (Nexavar)
  • Sunitinib (Sutent)

    Pharmacological and medical categories:

  • Anti cancer drugs
  • Antineoplastic medicines
  • EGFR inhibitors
  • NSCLC treatment medications
  • Oncological treatment
  • Pancreatic cancer therapy

    ATC codes:

  • L - Antineoplastic and immunomodulating agents
  • L01 - Antineoplastic agents
  • L01X - Other antineoplastic agents
  • L01XE - Protein kinase inhibitors
  • L01XE03 - Erlotinib

    ICD-10 codes:

  • Malignant neoplasm of pancreas - C25
  • Malignant neoplasm of bronchus and lung - C34

    Indications and usage:

  • Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
  • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

    Dosage and administration:

  • The dose for NSCLC is 150 mg/day.
  • The dose for pancreatic cancer is 100 mg/day.
  • All doses of Tarceva should be taken on an empty stomach at least one hour before or two hours after food.
  • Reduce in 50 mg decrements, when necessary.

    Adverse reactions, side effects:

  • The most common adverse reactions (>20%) in maintenance treatment are rash-like events and diarrhea.
  • The most common adverse reactions (>20%) in 2nd line NSCLC are rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, infection and vomiting.
  • The most common adverse reactions (>20%) in pancreatic cancer are fatigue, rash, nausea, anorexia, diarrhea, abdominal pain, vomiting, weight decrease, infection, edema, pyrexia, constipation, bone pain, dyspnea, stomatitis and myalgia.

    Pregnancy categories:

  • C - Australia (Risk cannot be ruled out)
  • N - United States (Not classified yet)

    Salts and other forms:

  • Erlotinib Base

    Synonyms, international and chemical names:

  • Erlotinibe
  • Erlotinibi
  • Erlotinibum
  • Erlotynib

    Brands, generics, trade names:

  • Erlocip - Cipla
  • Erlonat - Natco Pharma
  • Erlotinib - Mylan
  • Tarceva - Roche, Genentech, OSI Pharmaceuticals, Schwarz Pharma
  • Zyceva - Zydus pharmaceuticals

    Updated: February 2020
    Reviewed: February 2020
    About Us | NEWSbriefs | Contact Us | © 2020